ATP1B3
ENSG00000069849
Target class
Transporter
Chromosome
3
Approved drugs
4
Clinical candidates (approved and in development)
6
- Approved drugs
- 4
- Clinical candidates (approved and in development)
- 6
- Chemical probe available
- No
- Target name
- ATP1B3
- Gene name
- ATPase Na+/K+ transporting subunit beta 3
- Gene symbol
- ATP1B3
- Protein name
- Sodium/potassium-transporting ATPase subunit beta-3 (Sodium/potassium-dependent ATPase subunit beta-3) (ATPB-3) (CD antigen CD298)
- FLJ29027
- CD298
- Gene biotype
- Protein coding
- Gene family
- CD molecules|ATPase Na+/K+ transporting subunits
- Target class
- Transporter
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 225.75
- Tissue specificity (Gini)
- 0.316
- Tissue specificity (tau)
- 0.616
- KEGG gene identifiers
- hsa:483
- Protein interaction confidence
- 0.851269
- Protein interaction partners
- 26
- R-HSA-210991
- R-HSA-5578775
- R-HSA-936837
- R-HSA-9679191
- End position
- 141926549
- Start position
- 141876124
- Chromosome
- 3
- Strand
- Forward
- Apical cell membrane
- Single-pass type II membrane protein . Basolateral cell membrane
- Single-pass type II membrane protein . Melanosome . Note=Identified by mass spectrometry in melanosome fractions from stage I to stage IV.
- Plasma membrane
Publication evidence
- PubMed 17081065
- Tissue specificity (tau)
- 0.616418
- Expression inequality (Gini)
- 0.316095
Expression in transcripts per million
- Skin - Sun Exposed (Lower leg)
- 225.75
- Skin - Not Sun Exposed (Suprapubic)
- 223.35
- Vagina
- 190.5
- Lung
- 178.19
- Esophagus - Mucosa
- 161.78
Expression in transcripts per million
- Skin - Sun Exposed (Lower leg)225.75
- Skin - Not Sun Exposed (Suprapubic)223.35
- Vagina190.5
- Lung178.19
- Esophagus - Mucosa161.78
- Artery - Aorta155.4
- Adipose - Visceral (Omentum)154.94
- Artery - Coronary141.8
- Brain - Cerebellar Hemisphere140.6
- Cells - Cultured fibroblasts140
- Nerve - Tibial133.66
- Cells - EBV-transformed lymphocytes125.3
- Small Intestine - Terminal Ileum114.62
- Artery - Tibial113.84
- Brain - Cerebellum112
- Testis110.98
- Colon - Transverse109.86
- Adrenal Gland101.7
- Fallopian Tube100.79
- Adipose - Subcutaneous100.47
- Uterus100.13
- Pituitary94.76
- Prostate92.34
- Ovary90.81
- Cervix - Endocervix89.43
And 29 more, listed on the interactive page.
- GO:0006883
- GO:0030007
- GO:0035725
- GO:0036376
- GO:0050821
- GO:0071805
- GO:0072659
- GO:0086009
- GO:1903278
- GO:1903288
- GO:1990573
- GO:0005886
- GO:0005890
- GO:0036126
- GO:0070062
- GO:0001671
- GO:0005515
- GO:0030674
- GO:0051117
- GO:0141109
atrioventricular block
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: atrioventricular block
- renal
- cardiovascular
PubMed 28216264decreased heart rate
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased heart rate
- renal
- cardiovascular
PubMed 28216264increased urine excretion
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased urine excretion
- renal
- cardiovascular
PubMed 28216264vomiting
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: vomiting
- renal
- cardiovascular
PubMed 28216264increased cardiac contractility
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased cardiac contractility
- renal
- cardiovascular
PubMed 28216264cardiac arrhythmia
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: cardiac arrhythmia
- renal
- cardiovascular
PubMed 28216264increased urinary sodium excretion
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased urinary sodium excretion
- renal
- cardiovascular
PubMed 28216264ventricular fibrillation
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: ventricular fibrillation
- renal
- cardiovascular
PubMed 28216264
Related records
Trials (335)
- 3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain
- A 3-Part, Open-Label, Drug-Drug Interaction Study of Concomitant Administration of E2609 With Itraconazole, Rifampin, Digoxin, or Donepezil
- A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone
- A Clinical Study Comparing Anti-HER2 Therapy Combined With Chemotherapy to Chemotherapy Alone as Adjuvant Therapy Following Surgery for Stage IB-II Gastric Cancer With High HER2 Expression.
- A Clinical Study to Assess the Effect of Enlicitide on How the Body Processes Digoxin in Healthy Adult Participants (MK-0616-031)
- A Clinical Trial of Patients With Melanoma
- A Clinical Trial to Evaluate JAB-21822 Drug-drug Interactions in Healthy Subjects
- A Clinical Trial to Investigate the Clinical Drug-Drug Interaction of Divarasib With Probe Substrates of P-Glycoprotein and Breast Cancer Resistance Protein in Healthy Participants
- A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors
- A Drug Drug Interaction (DDI) Study of Baricitinib (LY3009104) and Digoxin in Healthy Participants
- A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Digoxin (P-Glycoprotein Substrate) in Healthy Participants
- A Drug Drug Interaction Study to Evaluate the Effect of VCT220 on the Pharmacokinetics of Repaglinide, Rosuvastatin, and Digoxin in Healthy, Overweight, and Obese Subjects
- A Drug Interaction Study of ACH-0145228
- A Drug Interaction Study of Albiglutide and Digoxin
- A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects.
- A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors
- A Drug-Drug Interaction Study Between XW003 and Metformin, Warfarin, Rosuvastatin or Digoxin
- A Drug-Drug Interaction Study Evaluating the Perpetrator Potential of DC-806 on Cocktails of CYP450 Enzyme and Transporter Substrates in Healthy Participants
- A Drug-drug Interaction Study Evaluating the Perpetrator Potential of LY4100511 (DC-853) on Midazolam, Repaglinide, Digoxin, Rosuvastatin in Healthy Participants
- A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib
Drugs (6)
- Acetyldigitoxin Sodium/potassium-transporting ATPase inhibitor
- Deslanoside Sodium/potassium-transporting ATPase inhibitor
- Digitoxin Sodium/potassium-transporting ATPase inhibitor
- Digoxin Sodium/potassium-transporting ATPase inhibitor
- Istaroxime Sodium/potassium-transporting ATPase inhibitor
- Lanatoside C Sodium/potassium-transporting ATPase inhibitor